Senolytic Drug Fisetin Reduces Atrial Fibrillation Risk in Aging Hearts
New research shows removing senescent cells with fisetin dramatically reduces dangerous heart rhythm disorders in aging rabbits.
Summary
Scientists discovered that senescent cells in aging hearts create inflammation that triggers atrial fibrillation, the most common dangerous heart rhythm disorder in older adults. Using aging rabbits, researchers found that treatment with fisetin, a natural senolytic compound, eliminated most senescent heart cells and dramatically reduced the risk of developing irregular heartbeats. The study showed aged rabbits had prolonged electrical signals and increased arrhythmia susceptibility, similar to elderly humans. After fisetin treatment, inflammatory markers dropped significantly and abnormal heart rhythms became much less likely to occur, all without impairing normal heart function.
Detailed Summary
Atrial fibrillation affects millions of older adults and significantly increases stroke and death risk. This groundbreaking study reveals that senescent cells in aging hearts create the inflammatory environment that makes dangerous irregular heartbeats more likely.
Researchers compared young and aged rabbits, finding that older animals developed the same electrical heart problems seen in elderly humans. Aged rabbit hearts contained many senescent cells producing inflammatory proteins called SASP factors. Human heart tissue samples confirmed this pattern exists in people with atrial fibrillation.
The team tested fisetin, a natural compound that selectively kills senescent cells. Short-term treatment eliminated most senescent heart cells in aged rabbits. This dramatically reduced their susceptibility to developing irregular heartbeats and decreased abnormal electrical activity that causes dangerous arrhythmias.
Crucially, fisetin improved heart rhythm stability without impairing normal heart function. The treatment specifically targeted the inflammatory, pro-arrhythmic environment created by senescent cells while preserving healthy cardiac tissue.
This research suggests senolytic therapy could prevent age-related heart rhythm disorders before they develop. Since atrial fibrillation often leads to stroke and heart failure, removing senescent cells might significantly extend healthy lifespan. The findings support the broader concept that cellular senescence drives multiple aging-related diseases through chronic inflammation. While human trials are needed, this study provides compelling evidence that targeting senescent cells could revolutionize cardiovascular disease prevention in aging populations.
Key Findings
- Fisetin treatment eliminated most senescent heart cells and reduced atrial fibrillation risk in aging rabbits
- Senescent cells in aging hearts produce inflammatory factors that promote dangerous irregular heartbeats
- Human atrial fibrillation patients show increased senescent cells and inflammatory markers in heart tissue
- Senolytic therapy improved heart rhythm stability without impairing normal cardiac function
- Inflammatory SASP factors correlated with left atrial enlargement, a known atrial fibrillation risk factor
Methodology
Researchers used young and aged New Zealand White rabbits, analyzing heart tissue through optical mapping, electrophysiology, and molecular techniques. Human atrial specimens from patients with and without atrial fibrillation were examined for comparison. Aged rabbits received fisetin treatment to assess effects on senescence and arrhythmia susceptibility.
Study Limitations
The study used rabbit models which may not fully translate to human physiology. Long-term safety and optimal dosing of fisetin in humans requires further investigation. Human clinical trials are needed to confirm these promising preclinical results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.